Inkontan (Trospium Chloride)

Trospium chloride blocks muscarinic receptors (M1‑M3) on the detrusor muscle of the bladder. By competitively antagonising these receptors, it prevents acetylcholine‑mediated contractions, thereby decreasing involuntary bladder activity and reducing urgency, frequency, and incontinence episodes.

The appropriate dose of Inkontan is determined by the prescribing healthcare professional based on the patient’s condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety of trospium chloride in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Inkontan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inkontan (trospium) is a quaternary ammonium compound, which limits its ability to cross the blood‑brain barrier, potentially reducing central nervous system side effects compared with tertiary amines such as oxybutynin. Its efficacy in controlling overactive bladder symptoms is comparable, while its safety profile may be more favourable for patients at risk of cognitive effects.

Store Inkontan at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Inkontan is taken orally, usually with water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional. Administration can be with or without food, but consistency with meals may help reduce gastrointestinal discomfort.

Serious adverse reactions include acute urinary retention, severe constipation leading to bowel obstruction, angle‑closure glaucoma, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience inability to urinate, severe abdominal pain, sudden vision changes, or signs of a severe allergic response.

Inkontan should be avoided in patients with known hypersensitivity to trospium or any excipients, those with narrow‑angle glaucoma, severe urinary retention, or uncontrolled narrow‑angle ocular disease. Caution is also advised for individuals with significant renal or hepatic impairment, and it is generally contraindicated during pregnancy unless clearly indicated.